Member Info for The_Paladin

Spacman’s theory is fanciful and most likely improbable. It does at least offer an explanation for the recent major hires by the company.

Why otherwise was John Ward replaced, when Helen Gearing might easily have stepped up from her current role to assume the vacant CFO position? This would have saved the company at least 0.2m p.a.

Why appoint a CMO, when the P2 trial protocols haven’t yet been completed? The appointee advised the company during their last two trials, both of which were unsuccessful? Surely, if it was deemed necessary to appoint a CMO, a candidate who had contributed to successful outcomes elsewhere should have been brought in?

When the trial protocols, and the P2 trials themselves finally arrive perhaps I will understand the company’s recruitment better than at present?

Until then, I remain puzzled at the choice of appointees, as well as the timing of these appointments?

Thank you Doc.D.

Frankly, I care little about the opinions of some contributors, who have always adopted a “loftier than thou” attitude, and formed badly judged opinions about the intentions of others.

Your earlier comment sums up exactly where the company is today. They have meandered using an oft quoted vague “strategy” for over a year without achieving very much. The market response is a good indicator of their success.

The next P2 trials, which offer a way forward, really are our last chance of recovering at least some of our massively depleted investments in this company. In retrospect, I wish that I had parted company when the share price was 30p+ just following the Sprinter announcement. I retain an optimistic outlook, but the CEO and Board have done nothing to allay my concerns during the last 20 months.

TD_19.

“As someone else said. If you watch this board long enough people’s true intentions are quite obvious.”

Now are you trying to be offensive, although I have no idea what you are alluding to? Explain please!

Perhaps if you took the trouble to read my comments before replying, you would realise how inappropriate your response is!

I seem to have touched a nerve there TommyD_19. However, as always, your arguments are perfectly sound. By now, I am perfectly aware of the time scale of clinical trials and the lengthy procedures involved during their planning and execution. My initial comment supported that.

The overall time frame of twenty months and counting, with deadlines being pushed forward on more than one occasion is a different matter. This is what I was alluding to when offering an opinion that the company probably lacked the expertise to go it alone in the last P3 trial? One would hope that they will have learned from past mistakes as we approach the next set of trials? I remain hopeful of a successful outcome to the forthcoming P2s. Time will tell.

Any investor who regularly follows the more intelligent contributions to this forum will not expect any imminent, game changing RNSs.

The height of my expectations are trial protocol announcements in February 2024, with the P2 trials following at a later indeterminate date in H1. Should these expectations be exceeded I shall be pleasantly surprised.

I accept the comments from the forum apologists for the conduct of the CEO and Board without reservation. These reasonable arguments offer a feasible explanation as to the excruciating length of time it has, and continues to take to get another trial underway. It suggests to me that the “go it alone” strategy that Synairgen adopted for their last P3 trial was unwise. Higher level expertise on board would undoubtedly have speeded up the process, as might well have been the case on this occasion.

The Synairgen share price touched on a 52-week low yesterday. Some investors on this forum view this as an opportunity. I am unable to make any sense of it?

Our CSO presented promising COPD trial data in Boston last week.

We have two independent highly promising sets of Lancet peer-reviewed Covid-19 P2 data.

Every in vitro test conducted, with a myriad of viruses, has yielded a positive outcome.

The safety record of SNG001 in all trials is flawless.

All this doesn’t seem to count for anything, as the current share price clearly affirms. This is because none of this is leading to income generation.

I have serious concerns about the recent initiatives of the CEO and Board.

Why was a CMO appointed while company led P2 trial protocols have yet to be announced, let alone the commencement dates of the trials themselves? Sometime during H1 2024 is too vague, especially as the company has had 20 months and counting to prepare?

Why was it necessary to replace the CFO with an additional appointment when Helen Gearing, a highly qualified CFO candidate, was already in position? She is a member of the company’s leadership team with little to do at present?

The premature appointments of five high level leaders in 2021 has probably cost the company £1-2m in salaries and other employee benefits to date. There is no evidence of any useful contribution from any of these employees. It is not their fault that they were appointed, only to discover that their roles were superfluous to requirement.

I can only hope that my concerns turn out to be unfounded and that the CEO and Board have not repeated the hugely costly errors made in 2021.

Meanwhile, we LTIs can but sit on our hands. Perhaps the company is working “at haste”, and we will receive significant news which will result in a reversal of the continued share price decline soon?

Could somebody elaborate where and when did Sept 24, 2024 arise ? Anyone who can calculate a company’s cash runway to that accuracy - more than eleven months ahead, with so many unknowns included in the overall cash burn is wasted on this forum.

Why not focus on positives. As I stated previously, the market is not accounting for Synairgen’s positive data, and patented products. Consequently, the share price is lower than it ought to be at the present time.

I am looking forward to several announcements in the coming months once the P2 trials have commenced. It has indeed been a long and difficult wait for something significant to emerge. Meanwhile, our patience must endure for a while longer.

Our star seems to be rising, although I am not reading too much into the following message yet. The future definitely looks brighter! :

“ As per DelveInsight Business Research LLP’s analysis, the diagnosed prevalent population of Obstructive Pulmonary Disease (COPD) in the 7MM was 33 million in 2022. These cases of COPD in the 7MM are expected to increase throughout the study period (2019–2032). The COPD market size was found to be USD 12.3 billion in 2022 in the 7MM and is anticipated to grow owing to the launch of new therapies in the market.

Leading pharma and biotech giants such as Genentech, GSK, Verona Pharma, Regeneron, Sanofi, MedImmune, EpiEndo Pharmaceuticals, Tetherex Pharmaceuticals Corp, AstraZeneca, CHIESI FARMACEUTICI S.P.A., Synairgen Research Ltd., Mereo BioPharma, Organicell Regenerative Medicine, Pulmotect, Inc., Inmunotek, Pulmatrix Inc., Glenmark Pharmaceuticals, Dimerix Limited, ProterixBio, Inc, among others are actively developing novel COPD drugs to improve the treatment scenario.

Get a detailed overview of how the COPD market will evolve by 2032:

https://lnkd.in/dW3s5qQK”

I stated my opinion as to why the CFO change may have come about earlier today. I do not believe that there is anything sinister or manipulative afoot. An individual, who has remained in a position for 20 years has inevitably fulfilled the requirements of his post to the expected standard. I can but wish John Ward well in any future endeavours.

I agree that none of Synairgen's recent activity has had a negative impact on the share price. Dividing the current cash balance by the number of shares yields the current share price. It makes no sense whatsoever for the market to lower it. What is clear is that the market is not attributing any value whatsoever to the company's intellectual property including patents, and trial data. This makes little sense either?

Investors can but wait patiently until the P2 trials are underway. I have a personal view as to how this investment may develop in the future. Mine is not a negative opinion. I may be rather impatient about the time scale involved, but retain a high degree of positivity about the process itself.

JW: "I don’t know the figure off hand".

I didn't attend the AGM, but if those were the CFO's words, then he was inadequately prepared.

"Question.: Have you shared this transcription notes here before today Doc83, or tis this the first outing ?"

I referred briefly to Doc83's information at the end of my earlier contribution. You can read it as part of the extensive feedback from Doc83, Wigster77, and others following the AGM. I was surprised to discover that our CFO was apparently unprepared for straightforward questions from investors. Synairgen is currently a tiny biopharmaceutical research company without any income streams. The accounting procedures should be uncomplicated at the current time.

The CEO continues to place senior executives in position with nothing but an outline strategy in place? Why couldn't Helen Gearing have been offered an interim CFO position pending future progress?

We are currently identifying suitable cohorts for P2 trials financed by the company. Nothing else? The date for these trials' commencement is set for sometime during H1 2024? Yet ,we recently appointed a CMO, when there is no real need of one for the time being?

The CEO and Board have made huge errors with premature appointments to the senior leadership group IMO. Since 2021, we have four additional senior execs, with little to do at present, in situ, and the share price has performed abysmally over the last 18 months. Yet the CEO and Board continue to add additional cash burn to Synairgen's dwindling resources. The latter is most probably the capital from the last cash raise? Why aren't they more prudent, at least until they are finally able to make a positive announcement regarding the company's future? By this, I mean something to reassure the market, and reawaken investor interest.

On the subject of fiscal prudence, why is Dr. Monk presenting data from a trial, conducted in 2020, in Boston? Surely, he and his team should by now be fully focused on bringing about the necessary developments before launching the P2 trials in H1?

Finally, looking back on the detailed reports that attendees at the last AGM kindly shared with this forum, it appears that the previous CFO failed to answer relatively straightforward questions from investors? Could this have contributed to his resignation?

Thank you Brand. Your vigilance, and sharing of quality information is appreciated, as always.

I wish that I could say the same thing about Synairgen. The Peer Review will eventually appear on the company's website, as well as on Synairgen's LinkedIn and X (twitter) spaces - when it pleases them! Whatever happened to the promise of improved communication from the last AGM?

"the problem is market fatigue and absolute disinterest - exhaustion really with the whole Synairgen saga, and the company does nothing to address that."

These facts, as I see them, bear out Spacman's statement:

1. Synairgen shares have traded at below 10p since the beginning of May.

2. The share price has traded in the range of 6.5p to 24.5p during the last 12 months.

3. Unless something changes before the New Year, the year high will drop to 16.5p. That peak value was a spike during a single day, which happened briefly with no underlying explanation?

4. Nothing of substance has emerged since February 2022. Some of our capital reserve has been spent (wisely perhaps in the long term?) on enhanced data analysis of the Sprinter trial results, and those from earlier trials. The summative data from the various analyses has been extensively presented at important conferences, with no meaningful reaction? The nebulous messages that investors were fed by there CEO about ongoing consultation at haste with potential partners of various descriptions have amounted to nothing.

5. As far as I am aware, the five senior executives, appointed in 2021, have contributed little, if nothing, of benefit to the company? Neither have the various paid consultants, who regularly accompanied the Synairgen team on the conference circuit. Our former SVP/Communications has since found employment elsewhere. This week a former consultant has joined the senior executive team as CMO.

6. The company has had no income since the cash raised to fund the last P3 trial.

7. Although the current strategy is potentially the most promising development in 18 months, a lengthy process with no guarantee of success lies ahead? It is my understanding that as a result of investor disaffection with lack of communication from the company, we will be informed as to how the processes leading to the P2 trials will evolve? Given a successful outcome to the latter, IMO we will need a P3 trial partner both for funding, and to provide an appropriate level of expertise to enhance our chance of success?

Perhaps my arguments are not balanced? After 18 months, we still need to turn a corner to get the company back on track. It is high time for the CEO and Board to announce something significant to change the way that the market has viewed this company for some considerable time. Surely all investors are by now becoming fatigued with their vague statements, persistent extension of trial deadlines, and general lack of progress? Is there any wonder that the share price is struggling? The company has done very little as yet to convince the market that there is, perhaps, an upward trajectory ahead of us?

Is it illegal to sell a block of shares, causing a substantial drop in the share price, and subsequently to buy them back under a different identity, perhaps?

I worked out that had I been able to sell my shares at last week’s high price, and bought back this morning, I could have made a £10K profit.

I am a relatively small holder. A significant seller might have made a considerable interim profit, while waiting for further development of IQ-AI’s strategy,

Someone has deliberately caused the share price to crash over two days? There is no news, or rationale, to support this manufactured collapse? The question begs why is someone manipulating the share price in this way? As a long term holder, I would like some answers.

“We now have a top-class CMO joining the ranks to get SNG001 global.”

You are right Fruitsnveg. I fail to see the significance of this latest appointment? From your comment, you are anticipating a successful outcome to the P2 trials, which will commence sometime during H1 2024. Further, we will then need funding for a P3 trial, which to my reckoning would take a further 1-2 years to completion? Before any of this can happen, there is the matter of analysing the samples from Southampton CTU’s UNIVERSAL trial in order to determine an appropriate cohort for the P2 trials.

All investors desire global success for this company. We were close to achieving this, but we’re thwarted by an unfortunate series of circumstances, some of which were beyond our control. Meanwhile, I still fail to see the short term value that the appointment of a CMO today will add to the necessary steps to achieve another P3 trial? Your comment concerning a cash runaway to mid 2024 serves to add to my doubts.

Wpa5

I used the same argument about the three senior executives that were appointed in 2021 in anticipation of a successful P3 trial outcome. They are still on the payroll, and there is no evidence that they have contributed anything of benefit to the company?

Similarly, can a, by now, vastly diminished company with no income that is funding its own minimal P2 trials justify the appointment of yet another senior executive? I sincerely hope that there is a good reason for this appointment? I fail to see how a CMO, as opposed to an external consultant, can add any value to the current ongoing strategy?

The company is using a recruitment consultant, and social media to fill this position. It is not advertised on Synairgen’s website.

The website is not being fully utilised, and has not been updated for a considerable time. This ought to be the case in order to convey the fact that Synairgen is up and running, and bringing its strategy to the fore. Previously, the time spent by Brooke Clarke on the pointless twitter/LinkedIn carousel, which achieved nothing, would have been better spent on updating the website IMO.

So many other companies likewise spend a considerable sum on the production of an impressive website. Subsequently, they give it very little attention. The website is one method of updating and reassuring investors. It would be helpful if Synairgen, who provide very little information, took this simple measure. It would be an improvement of the sporadic breadcrumbs which investors on this forum sometimes discover by accident, and kindly share with the rest of us!

A neutral RNS only. Less than I had hoped for at this stage.

How focused is our CEO on this business? As well as his involvement with RTOP, his name keeps cropping up with various Italian crypto training initiatives. Is this his next big project?

Surely, Mr. Zamboni must by now realise that investor confidence in SYME is slowly waning. It is high time for him and his colleagues to address the under delivery that was so apparent earlier today? Promises are no longer enough. Investors need to be shown actual progress.

The future potential remains, but more progress needs to be demonstrated imminently.